Overview

A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Status:
Withdrawn

Trial end date:
2018-10-15

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double blind, placebo controlled parallel group clinical study. Following a screening period of up to 28 days, eligible subjects will be randomized to receive adjunct treatment to oral LD/DDI (Dopa Decarboxylase Inhibitor) with continuous subcutaneous infusion of ND0612 or matching placebo for 16 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

NeuroDerm Ltd.

Treatments:

Carbidopa
Levodopa
Pharmaceutical Solutions